Cormorant Group Buys $5M in BlossomHill IPO, Converts $52.8M Preferred Stake

summarizeSummary

Cormorant Asset Management, a major pre-IPO investor and 10% owner, bought $5 million in BlossomHill's IPO at $16.00 and converted $52.8 million in preferred stock, signaling strong commitment as the stock trades near its low.

check_boxKey Events · Ownership and Investor Activity · BLSM

• $5M Open-Market Purchase at IPO Price

  Cormorant Global Healthcare Master Fund bought 312,500 shares at $16.00, the IPO price, for a total of $5,000,000 on August 10, 2026.

• $52.8M Preferred Stock Conversion

  Upon the IPO closing, 3,301,534 shares of Series A and Series B Preferred Stock automatically converted into common stock, representing a pre-IPO investment now valued at approximately $52.8 million based on the IPO price.

• Post-Transaction Holdings of 3.6M Shares

  After the purchase and conversion, the Cormorant group holds 3,614,034 common shares, making them a significant post-IPO shareholder.

• Director Option Grant

  Bihua Chen, a director and manager of Cormorant, received 23,904 stock options with an exercise price of $16.00, vesting monthly over three years.

auto_awesomeAnalysis · BLSM · Life Sciences

On the day BlossomHill went public, Cormorant Asset Management and its affiliated funds—led by director Bihua Chen—reinforced their commitment with a $5 million open-market purchase of 312,500 shares at the $16.00 IPO price. At the same time, they converted 3.3 million shares of preferred stock into common, lifting their total post-IPO common holdings to 3.6 million shares. The purchase stands out as a strong conviction signal from a pre-IPO insider group that already held a sizable stake, particularly with the stock trading near its 52-week low. While the conversion removes the preferred overhang, it also adds to the public float. Chen additionally received a standard director option grant of 23,904 shares.